ES2067842T3 - Uso del factor de necrosis tumoral. - Google Patents

Uso del factor de necrosis tumoral.

Info

Publication number
ES2067842T3
ES2067842T3 ES91200520T ES91200520T ES2067842T3 ES 2067842 T3 ES2067842 T3 ES 2067842T3 ES 91200520 T ES91200520 T ES 91200520T ES 91200520 T ES91200520 T ES 91200520T ES 2067842 T3 ES2067842 T3 ES 2067842T3
Authority
ES
Spain
Prior art keywords
necrosis factor
tumor necrosis
disease
demyelinatig
uveitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91200520T
Other languages
English (en)
Inventor
Yoshiki Otsuka
Kazuyoshi Hori
Hiroshi Hayashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asahi Kasei Corp
Asahi Chemical Industry Co Ltd
Original Assignee
Asahi Chemical Industry Co Ltd
Asahi Kasei Kogyo KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2056734A external-priority patent/JPH03261726A/ja
Priority claimed from JP2056736A external-priority patent/JPH03261725A/ja
Priority claimed from JP2056735A external-priority patent/JPH03261724A/ja
Application filed by Asahi Chemical Industry Co Ltd, Asahi Kasei Kogyo KK filed Critical Asahi Chemical Industry Co Ltd
Application granted granted Critical
Publication of ES2067842T3 publication Critical patent/ES2067842T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Dental Tools And Instruments Or Auxiliary Dental Instruments (AREA)
  • Materials For Medical Uses (AREA)
  • Telephonic Communication Services (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

SE FACILITA UNA COMPOSICION FARMACEUTICA Y UN METODO PARA SU USO EN EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS CRONICAS Y SEVERAS, COMO ENFERMEDAD DEMYELINATING, UVEITIS Y GRAFT-VERSUS-HOST-DISEASE. LA COMPOSICION INCLUYE UN FACTOR DE NECROSIS DE TUMOR COMO INGREDIENTE ACTIVO Y POR LO MENOS UN TRANSPORTADOR ACEPTABLE FARMACEUTICAMENTE, DILUENTE O EXCIPIENTE.
ES91200520T 1990-03-09 1991-03-08 Uso del factor de necrosis tumoral. Expired - Lifetime ES2067842T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2056734A JPH03261726A (ja) 1990-03-09 1990-03-09 ぶどう膜炎治療用医薬組成物
JP2056736A JPH03261725A (ja) 1990-03-09 1990-03-09 移植片対宿主の疾患治療用医薬組成物
JP2056735A JPH03261724A (ja) 1990-03-09 1990-03-09 脱髄性疾患治療用医薬組成物

Publications (1)

Publication Number Publication Date
ES2067842T3 true ES2067842T3 (es) 1995-04-01

Family

ID=27296018

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91200520T Expired - Lifetime ES2067842T3 (es) 1990-03-09 1991-03-08 Uso del factor de necrosis tumoral.

Country Status (11)

Country Link
US (1) US5190750A (es)
EP (1) EP0445894B1 (es)
AT (1) ATE118221T1 (es)
AU (1) AU633196B2 (es)
CA (1) CA2037831C (es)
DE (2) DE4107554A1 (es)
DK (1) DK0445894T3 (es)
ES (1) ES2067842T3 (es)
FR (1) FR2659235A1 (es)
GB (1) GB2241891B (es)
GR (1) GR3015840T3 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL106720A (en) * 1992-08-17 1998-10-30 Autoimmune Inc The use of antigen bystander in the preparation of compositions for the treatment of neurologically related diseases in mammals and such compositions
BR9507452A (pt) * 1994-04-08 1997-08-05 Brigham & Womens Hospital Composição farmacêutica uso de um polipeptídeo não-interferon uso de uma quantidade de um antígeno padronizado e uma quantidade de um polipeptídeo não-interferon e produto contendo (1) uma quantidade de um antígeno padronizado e (11) uma quantidade de um polipeptídeo não-interferon
AU740405B2 (en) * 1998-05-15 2001-11-01 Genentech Inc. IL-17 homologous polypeptides and therapeutic uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62292727A (ja) * 1986-06-12 1987-12-19 Dainippon Pharmaceut Co Ltd 癌壊死因子を有効成分とする鎮痛・消炎剤
JPS6330426A (ja) * 1986-07-25 1988-02-09 Mitsubishi Chem Ind Ltd 自己免疫性疾患治療薬
DE3631413A1 (de) * 1986-09-16 1988-03-24 Knoll Ag Therapeutisches system zur lokalen applikation von pharmawirkstoffen
US4929442A (en) * 1986-09-26 1990-05-29 Exovir, Inc. Compositions suitable for human topical application including a growth factor and/or related materials
US4963354A (en) * 1987-01-21 1990-10-16 Genentech, Inc. Use of tumor necrosis factor (TNF) as an adjuvant
IL83878A (en) * 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
AU2844889A (en) * 1988-01-22 1989-07-27 Collagen Corporation Method for suppressing the growth of normal and cancer cells
DE3839639A1 (de) * 1988-11-24 1990-05-31 Basf Ag Verwendung von tnf bei der behandlung von hautkrankheiten
CA2003981C (en) * 1988-12-27 2000-06-13 Hiroshi Ishimaru Pharmaceutical compositions and use thereof in the treatment of psoriasis

Also Published As

Publication number Publication date
DK0445894T3 (da) 1995-04-03
DE69107226T2 (de) 1995-05-24
GB2241891A (en) 1991-09-18
AU7281091A (en) 1991-09-12
FR2659235A1 (fr) 1991-09-13
CA2037831A1 (en) 1991-09-10
DE4107554A1 (de) 1991-10-10
DE69107226D1 (de) 1995-03-23
GB9104927D0 (en) 1991-04-24
AU633196B2 (en) 1993-01-21
US5190750A (en) 1993-03-02
GR3015840T3 (en) 1995-07-31
GB2241891B (en) 1994-05-25
EP0445894A3 (en) 1992-01-02
CA2037831C (en) 1997-01-21
ATE118221T1 (de) 1995-02-15
EP0445894B1 (en) 1995-02-08
EP0445894A2 (en) 1991-09-11

Similar Documents

Publication Publication Date Title
ES2179040T3 (es) Utilizacion de 5-fluoro-2'-desoxi-3'-tiacitidina para el tratamiento de la hepatitis b.
MXPA04000920A (es) Derivados de aminoisoxazol activos como inhibidores de la cinasa.
MX9200361A (es) Nuevo uso del antagonista de adenosina.
NO933028D0 (no) Peg-interferonkonjugater
PT723538E (pt) Compostos triciclicos de carbamato uteis para a ainibicao da funcao da proteina g e para o tratamento de doencas proliferativas
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
ES2045182T3 (es) Substancias fisiologicamente activas, un proceso para la preparacion de las mismas y composiciones farmaceuticas que las contienen.
DE69426334D1 (de) Parenterales Busulfan zur Behandlung von malignen Krankheiten
ECSP930933A (es) Composicion farmaceutica y procedimiento para prepararla
DE69429591D1 (de) Therapeutisch wirksame Verbindungen
DE69728914D1 (de) Pharmazeutische Zusammensetzung gegen durch Papillomaviren verursachte Tumoren und Infektionen
CA2041417A1 (en) Treatment of pancreatic disease with 15-keto-prostaglandin compounds
ES2193246T3 (es) Cefalosporinas antibacterianas.
CA2046069A1 (en) Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
BG93298A (bg) Имуностимулиращи 6-арил-5,6-дихидроимидазо(2,1-в)тиазолови производни
CA2027814A1 (en) Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
CA2135179A1 (en) Pharmaceutical Compositions of Alkylsulphonamides 5HT1 Agonists for Rectal Administration
IT1249650B (it) N-(5-tioxo-l-prolil)-l-cisteina e suoi derivati, loro preparazione ed impiego terapeutico
DK658889D0 (da) Farmaceutisk praeparat til brug ved behandling af psoriasis
DK0445894T3 (da) Anvendelse af tumornekrosefaktor
NO810480L (no) Anologifremgangsmaate for fremstilling av terapeutisk aktive 1,3,4-oksadiazolylfenol-derivater
RU94040865A (ru) Производные пептида и их терапевтически приемлемые соли, способ их получения, фармацевтическая и косметическая композиция с антивирусной активностью
ATE106732T1 (de) Arzneimittelzubereitung, enthaltend stigmasta-4- en-3-on sowie deren verwendung.
FI890173L (fi) Isoxazoler med nootropisk verkan.
AP9200405A0 (en) Pharmaceutical formulations comprised of micronised halofantrine.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 445894

Country of ref document: ES